The drug is designed for outpatient treatment of complicated urinary tract infections and complicated intra-abdominal infections caused by multi-drug resistant pathogens. The Phase I study demonstrated a promising safety profile, with no serious adverse events reported, paving the way for further clinical trials.
Wockhardt Limited has informed the Exchange regarding a press release dated October 07, 2024, titled "Wockhardt's another breakthrough antibiotic: once-a-day β-lactam enhancer, WCK 6777 (Ertapenem/Zidebactam) with unique out-patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US".